We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > Seres

News List

Seres’ ulcerative colitis candidate misses primary endpoint in mid-stage study pharmatimes
July 26, 2021
Microbiome therapeutics company Seres Therapeutics has announced that a Phase IIb study of its potential ulcerative colitis (UC) candidate SER-287 failed to meet its primary endpoint.
Seres and Nestlé enter up to $525m deal for microbiome therapeutic pharmaceutical-technology
July 05, 2021
Seres Therapeutics has signed an agreement with Nestlé Health Science to co-market the former’s investigational treatment, SER-109, for recurrent Clostridioides difficile infection (CDI) in the US and Canada.
AstraZeneca and Seres Therapeutics to study new cancer therapy process pharmaceutical-technology
March 13, 2019
AstraZeneca has formed a research alliance with US-based Seres Therapeutics to explore the use of microbiome in boosting the efficacy of cancer immunotherapy.
Seres elevates CFO Eric Shaff to CEO post as it advances immunology therapies fiercebiotech
January 17, 2019
Seres Therapeutics is promoting its chief operating and financial officer, Eric Shaff, to succeed Roger Pomerantz as its new president and CEO......